Veeco Instruments Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied text does not provide standalone fourth-quarter financial results.
Business context
Veeco develops, manufactures, sells, and supports semiconductor and thin-film process equipment. Its end markets are Semiconductor, Compound Semiconductor, Data Storage, and Scientific & Other. It operates as one reportable segment. Parts, upgrades, service, and support represented approximately 22% of 2023 net sales.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $666.4 million | $646.1 million |
| Gross profit / gross margin | $285.1 million / 42.8% | $263.1 million / 40.7% |
| Operating income / operating margin | $69.9 million / 10.5% | $60.3 million / 9.3% |
| Net income (loss) | $(30.4) million | $166.9 million |
| Net cash from operating activities | $61.7 million | $108.5 million |
- Revenue rose 3% year over year. Semiconductor sales increased 12% to $412.7 million; Compound Semiconductor sales fell 28% to $87.3 million; Data Storage increased 1% to $88.5 million; and Scientific & Other increased 15% to $78.0 million.
- The 2023 net loss included $97.1 million of debt-extinguishment losses related to refinancing and repurchasing convertible notes. In 2022, net income included a $116.0 million income-tax benefit, primarily from releasing a valuation allowance; this makes year-to-year net income comparisons less representative of operating performance.
- Cash, cash equivalents, and short-term investments totaled $305.8 million at year-end, compared with $303.0 million in 2022. Operating cash flow declined, partly due to working-capital changes, including increased inventory.
- Outstanding convertible-note principal totaled $281.5 million: $26.5 million due 2025, $25.0 million due 2027, and $230.0 million due 2029. The $150.0 million revolving credit facility was undrawn at year-end.
- Year-end backlog was $490.7 million, versus $499.9 million in 2022. Inventory increased to $237.6 million from $206.9 million.
Material changes and unusual items
- Veeco issued $230.0 million of 2.875% convertible notes due 2029 and used proceeds to refinance portions of its 2025 and 2027 notes. The transactions extended average note maturity and reduced future cash interest, but generated $97.1 million in extinguishment losses and involved share issuance.
- Veeco acquired Epiluvac AB in January 2023 to enter the silicon carbide equipment market. Acquisition-date consideration was $56.4 million, including $26.1 million of contingent consideration. Epiluvac’s 2023 operating results were immaterial to Veeco.
- China accounted for $217.9 million, or 33%, of 2023 sales, up 76% from 2022. Sales outside the United States represented 76% of total sales.
Outlook, management commentary, and risks
- Management expects 2024 Semiconductor revenue to increase, Compound Semiconductor revenue to grow, and Data Storage revenue to be flat to up. Scientific & Other is expected to grow over the long term in line with GDP. These are management expectations, not guarantees.
- Management cited macroeconomic uncertainty, high interest rates and inflation, soft consumer, smartphone, and PC demand, and lower demand for some advanced-packaging lithography products, spare parts, and upgrades. Customers have also requested cancellations, shipment delays, or payment delays.
- U.S. export controls affecting China remain a significant risk. Veeco said the October 2023 regulatory update had not materially affected its business to date, but further restrictions could constrain sales and service and cause revenue loss.
- Other key risks include cyclical customer capital spending, concentrated customers and geographic exposure, order timing and cancellations, supplier and outsourcing dependence, inventory obsolescence, competition, rapid technology changes, and cybersecurity incidents. Veeco reported past cybersecurity incidents at the Company or third parties, but said it was not aware of any current incident or new threat with a material effect or reasonably likely material effect.
- Management believes cash, investments, and operating cash flow will cover working-capital needs and obligations for the next 12 months. Purchase commitments were $200.4 million, mostly due within one year, with $19.4 million of supplier deposits to be applied against them. Management reported no material expected adverse outcome from ongoing legal proceedings.
Important facts for investors to verify
- Whether forecast 2024 growth by end market materializes, particularly given the reduced backlog and market cyclicality.
- How export-control changes affect China sales, customer service, inventory, and the ability to replace restricted sales elsewhere.
- Whether inventory growth and purchase commitments convert into shipments and cash, or lead to cancellations, excess inventory, or cash-flow pressure.
- The cash, dilution, and refinancing implications of the convertible notes, including the 2027 notes’ stated conversion eligibility through March 31, 2024.
- Whether Epiluvac achieves its strategic milestones and order-based earn-out targets; contingent consideration was $24.2 million at year-end.
- The drivers of the 2023 net loss and the sustainability of margins and operating cash flow, separating operating trends from debt-extinguishment and tax-related effects.